Search results for "Agoni"

showing 10 items of 2493 documents

Prognostic Value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 Immunoreactivity in pT1 G3 Urothelial Bladder Carcinomas

2001

pT1 G3 bladder carcinomas are heterogeneous with respect to tumor recurrence and progression. Whereas some urologists treat these carcinomas by repeated transurethral resections often followed by intravesical chemotherapy or BCG instillation, others recommend cystectomy after tumor recurrence or early cystectomy after the initial diagnosis. Our goal was to determine the prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in these tumors. There were 30 patients with a new histopathological diagnosis of pT1 G3 urothelial carcinoma based on a transurethral resection specimen. Representative sections of these specimens were examined for the above markers. All patients…

Cyclin-Dependent Kinase Inhibitor p21medicine.medical_specialtyPathologyTime FactorsTumor suppressor genemedicine.medical_treatmentBcl 2 baxUrologyDisease-Free SurvivalCystectomyPredictive Value of TestsCyclinsProto-Oncogene ProteinsBiomarkers TumormedicineHumansNeoplasm InvasivenessRetrospective Studiesbcl-2-Associated X ProteinCarcinoma Transitional CellUrinary bladderBladder cancerbiologyMembrane ProteinsGeneral MedicinePrognosismedicine.diseaseImmunohistochemistrySurvival RateKi-67 Antigenbcl-2 Homologous Antagonist-Killer Proteinmedicine.anatomical_structureTransitional cell carcinomaProto-Oncogene Proteins c-bcl-2Urinary Bladder NeoplasmsTumor progressionKi-67biology.proteinTumor Suppressor Protein p53Follow-Up StudiesTumor Biology
researchProduct

“Cysteinyl leukotriene-1 receptor activation in a human bronchial epithelial cell line leads to signal transducer and activator of transcription 1-me…

2008

Abstract We studied the effect of leukotriene D(4) (LTD(4)) on a human bronchial epithelial cell line (16HBE) overexpressing the cysteinyl leukotriene (CysLT) (1) receptor (HBECysLT(1)R), looking at the associated signal transduction mechanisms as well as at effects on inflammatory cell adhesion. The results obtained showed that LTD(4) increases the phosphorylation of extracellular signal-regulated protein kinase (ERK) 1/2 and of the signal transducer and activator of transcription 1 (STAT-1) in serine 727 (STAT-1Ser727), resulting in increased eosinophil adhesion to HBECysLT(1)R, associated with enhanced surface expression of intercellular adhesion molecule (ICAM) 1. Pretreatment with a Cy…

CyclopropanesMAPK/ERK pathwayIndolesBronchiAcetatesSulfidesBiologyCysteinyl leukotriene-1cysteinyl leukotrieneCell LineLeukotriene D4MaleimidesInterferon-gammaCell AdhesionHumansProtein kinase ACells CulturedProtein kinase CReceptors LeukotrienePharmacologyKinaseMEK inhibitorMembrane ProteinsEpithelial CellsIntercellular Adhesion Molecule-1Intercellular adhesion moleculeCell biologyEosinophilsSTAT1 Transcription FactorQuinolinesLeukotriene AntagonistsMolecular MedicinePhosphorylationMitogen-Activated Protein KinasesSignal transduction
researchProduct

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus monteluk…

2004

BACKGROUND: Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms. OBJECTIVE: We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 microg given once daily, administered in mono-therapy or combined therapy with a H1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to Parietaria during natural pollen exposure. In addition, we examined the effect of…

CyclopropanesMaleAllergySettore MED/09 - Medicina Internamedicine.medical_treatmentseasonal allergic rhinitisAcetatesGastroenterologyImmunology and AllergyMedicineChildFluticasonepollen seasonRandomized placebo-controlled trialBlood Proteinsrespiratory systemEosinophil Granule ProteinsMiddle AgedCetirizineAnesthesiamontelukastHistamine H1 AntagonistsQuinolineseosinophil cationic proteinDrug Therapy CombinationFemaleeosinophilsmedicine.symptommedicine.drugAdultmedicine.medical_specialtyAdolescentImmunologyNasal congestionSulfidesPlaceboFluticasone propionateDrug Administration ScheduleRibonucleasesDouble-Blind MethodInternal medicineHumansRandomized placebo-controlled trial; fluticasone; cetirizine; montelukast; seasonal allergic rhinitisGlucocorticoidsMontelukastAdministration IntranasalAnalysis of Variancerhinorrheafluticasone propionatebusiness.industrynasal lavageRhinitis Allergic Seasonalmedicine.diseaseCetirizineAndrostadienesParietariaNasal sprayFluticasoneLeukotriene AntagonistsNasal administrationbusinessClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
researchProduct

Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist

2015

Chronic obstructive pulmonary disease (COPD) is characterised by chronic pulmonary inflammation punctuated by periods of viral exacerbations. Recent evidence suggests that the combination of roflumilast with corticosteroids may improve the compromised anti-inflammatory properties of corticosteroids in COPD. We analyzed differential and combination anti-inflammatory effects of dexamethasone and roflumilast N-oxide in human bronchial epithelial cells (HBECs) stimulated with viral toll like receptor (TLR) agonists. Lung tissue and HBECs were isolated from healthy (n = 15), smokers (n = 12) and smokers with COPD (15). TLR3 expression was measured in lung tissue and in HBECs. IL-8 secretion was …

CyclopropanesMaleAnti-Inflammatory AgentsDrug ResistanceAminopyridinesDexamethasonePulmonary Disease Chronic ObstructiveRoflimilastAdrenal Cortex HormonesToll like receptorsCells CulturedCOPDSmokingMiddle Agedmedicine.anatomical_structureBenzamidesCorticosteroidViral exacerbationDrug Therapy CombinationFemalePulmones - Enfermedadesmedicine.drugSignal TransductionAgonistPulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classCorticosteroid resistanceBronchiInternal medicinemedicineCOPDHumansInterleukin 8DexamethasoneRoflumilastAgedLungbusiness.industryResearchInterleukin-8Epithelial CellsAparato respiratoriomedicine.diseaserespiratory tract diseasesToll-Like Receptor 3EndocrinologyPoly I-CCase-Control StudiesTLR3businessRespiratory Research
researchProduct

Safety and efficacy of montelukast as adjunctive therapy for treatment of asthma in elderly patients

2013

Asthma is a disease of all ages. This assumption has been challenged in the past, because of several cultural and scientific biases. A large body of evidence has accumulated in recent years to confirm that the prevalence of asthma in the most advanced ages is similar to that in younger ages. Asthma in the elderly may show similar functional and clinical characteristics to that occurring in young adults, although the frequent coexistence of comorbid conditions in older patients, together with age-associated changes in the human lung, may lead to more severe forms of the disease. Management of asthma in the elderly follows specific guidelines that apply to all ages, although most behaviors ar…

CyclopropanesMalePediatricsmedicine.medical_specialtyQuinolineDiseaseReviewSettore MED/10 - Malattie Dell'Apparato Respiratorioairway inflammationAcetatesSulfidesAnti-asthmatic AgentMaintenance therapyleukotriene antagonistmedicineAnti-Asthmatic AgentHumansAnti-Asthmatic AgentsYoung adultMontelukastAsthmaAgedAged 80 and overLeukotrienetreatmentAcetatebusiness.industryagingGeneral MedicineasthmaMiddle Agedmedicine.diseaseClinical trialleukotriene antagonistsPhysical therapyQuinolinesFemaleGeriatrics and GerontologybusinessHumanmedicine.drugClinical Interventions in Aging
researchProduct

Can the response to Omalizumab be influenced by treatment duration? A real-life study

2017

Objective It is unknown whether Omalizumab effectiveness changes over the course of time. Our retrospective real-life study tried to analyze whether Omalizumab response may be influenced by treatment duration. Methods 340 severe asthmatics treated with Omalizumab for different periods of time were recruited. They were subdivided into 4 groups according to the Omalizumab treatment length: 60 months. Omalizumab treatment results (FEV1, exacerbations, ACT, SABA use, asthma control levels, medications used e and ICS doses) were compared. Results ACT, exacerbations, GINA control levels, ICS doses and SABA use were similar in all groups with different Omalizumab treatment durations. Using a linea…

CyclopropanesMaleSevere asthmaTime FactorsTreatment durationQuinolineEffectivenessOmalizumabOmalizumabAcetatesAdrenal Cortex Hormone0302 clinical medicineAdrenal Cortex HormonesRetrospective StudieForced Expiratory VolumeMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineLead (electronics)Adrenergic beta-AgonistConfoundingEffectiveneReal-lifeResponseAdrenergic beta-AgonistsMiddle AgedTreatment OutcomeEffectiveness; Omalizumab; Real-life; Response; Severe asthma; Treatment duration; Pulmonary and Respiratory Medicine; Biochemistry (medical); Pharmacology (medical)QuinolinesLinear ModelFemaleHumanmedicine.drugAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyTime FactorSulfidesSettore MED/10 - Malattie Dell'Apparato RespiratorioTreatment duration03 medical and health sciencesInternal medicineHumansAnti-Asthmatic AgentMontelukastRetrospective StudiesAsthmaAcetatebusiness.industryBiochemistry (medical)Retrospective cohort studymedicine.diseaseAsthmaDiscontinuationSurgery030228 respiratory systemLinear ModelsbusinessPulmonary Pharmacology & Therapeutics
researchProduct

Anti-inflammatory medications for the treatment of pediatric obstructive sleep apnea

2020

CyclopropanesPulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classAnti-Inflammatory AgentsAdministration OralAcetatesSulfidesAnti-inflammatorylaw.inventionRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansChildAdministration IntranasalMontelukastSleep Apnea Obstructivebusiness.industryInfantmedicine.diseaseObstructive sleep apneaTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthQuinolinesLeukotriene Antagonistsbusinessmedicine.drugPaediatric Respiratory Reviews
researchProduct

Efficacy, tolerability, and safety of montelukast versus finasteride for the treatment of moderate acne in women: A prospective, randomized, single-b…

2021

Background Acne is a chronic inflammatory skin disease which involves the pilosebaceous unit. Tissue inflammation isone of the crucial mechanisms, amongst others. Of the various cytokines, leukotriene B4 (LT-B4) is the most potentleucocyte chemotactic mediator. Montelukast is an antagonist of the LT-B4 receptor. Finasteride is an antiandrogen whichspecifically inhibits the 5α-reductase enzyme. Aims This study aimed at comparing the efficacy, tolerability and safety of montelukast versus finasteride in the treatmentof moderate acne in women. Patients/method This randomized, single-blinded, prospective trial over 12 weeks recruited 65 female subjects with moderate acne vulgaris (Global Acne G…

Cyclopropanesmedicine.medical_specialtymedicine.drug_classDermatologyAcetatesSulfidesAntiandrogenGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawInternal medicineAcne VulgarismedicineHumansProspective StudiesAdverse effectAcneMontelukastbusiness.industryFinasterideAntagonistmedicine.diseasechemistryTolerabilityFinasterideQuinolinesFemalebusinessmedicine.drugJournal of cosmetic dermatologyREFERENCES
researchProduct

Inhalable nano into micro dry powders for ivacaftor delivery: The role of mannitol and cysteamine as mucus-active agents.

2020

In this paper the innovative approach of Nano into micro (NiM9 was developed to produce Nanoparticles loaded Ivacaftor to incorporate into mannitol or mannitol/cysteamine micromatrices for drug pulmonary administration in CF. Nanoparticles composed by a mixture of two polyhydrohydroxyethtylaspartamide copolymers containing a loading of Ivacaftor of 15.5 % w/w were produced. These Nanoparticles were incorporated into microparticles to obtain NiM that were characterized in terms of size and size distribution, interaction with CF-AM by rheological and turbidimetric studies as well as by aerodynamic diameter measurements. Finally the activity of Ivacaftor into these NiM was evaluated by in vitr…

Cystic Fibrosisαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) copolymer PHEA ivacaftor mucus-penetrating nanoparticle cell penetrating peptide nano into micro strategy. CysteamineDrug CompoundingPharmaceutical ScienceNanoparticleCystic Fibrosis Transmembrane Conductance Regulator02 engineering and technologyQuinolonesAminophenols030226 pharmacology & pharmacyIvacaftor03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNano-Administration InhalationMucus-penetrating nanoparticlemedicineCopolymerAnimalsMannitolChloride Channel AgonistsCells CulturedExpectorantsCell penetrating peptideNano into micro strategyChemistry021001 nanoscience & nanotechnologyMucusRats Inbred F344IvacaftorCopolymer PHEADrug LiberationSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoMutationNanoparticlesCysteamineMannitolPowders0210 nano-technologyPeptidesαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA)medicine.drugNuclear chemistryInternational journal of pharmaceutics
researchProduct

A comparison of cytoplasmic and nuclear estradiol and progesterone receptors in human fallopian tube and endometrial tissue

1981

Quantitative and qualitative aspects of the in vitro binding of 3 H-estradiol and 3 H-progesterone to receptor components from human endometrium and fallopian tube cytoplasmic and nuclear fractions were studied. The steroid binding macromolecules formed in vitro could be extracted from nuclei by 0.4M KCl and detected by glycerol gradient centrifugation. Both estradiol- and progesterone-binding compounds formed only one peak (under high ionic strength conditions) with a sedimentation coefficient of about 4-5S. The number of cytoplasmic and nuclear binding sites for both estradiol and R5020 varied dramatically throughout the menstrual cycle: the estradiol and progesterone receptor concentrati…

Cytoplasmmedicine.medical_specialtymedia_common.quotation_subjectmedicine.medical_treatmentBiologyPromegestoneSteroidInfundibulumEndometriumInternal medicineProgesterone receptorFollicular phasemedicineHumansTissue DistributionReceptorFallopian TubesProgesteroneMenstrual cyclemedia_commonCell NucleusEstradiolObstetrics and GynecologyMenstruationCytosolEndocrinologymedicine.anatomical_structureReceptors EstrogenReproductive MedicineFemaleReceptors Progesteronehormones hormone substitutes and hormone antagonistsFallopian tubeFertility and Sterility
researchProduct